RNA start­up ADARx rais­es $200M from Bain, TCGX to bring RNAi 'to the next lev­el'

The RNA start­up ADARx Phar­ma­ceu­ti­cals has raised a $200 mil­lion Se­ries C, aim­ing to ad­vance mul­ti­ple clin­i­cal pro­grams that di­rect­ly chal­lenge the lead­ers of the RNA in­ter­fer­ence space.

The San Diego biotech an­nounced the round, led by Bain Cap­i­tal Life Sci­ences and TCGX, on Wednes­day and plans to grow from 50 to 80 em­ploy­ees over the next year. ADARx emerged from stealth in the fall of 2021 along­side a $75 mil­lion Se­ries B round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.